UTv Videos

Mustafa J. Saleh, MD, highlights new research exploring whether germline-based polygenic risk scores could help predict outcomes for patients with kidney cancer.

On Hugo's modular arm architecture, Porter contrasts it with the traditional "boom" design that has dominated robotic surgery for over 2 decades.

Maha H. A. Hussain, MD, FASCO, FACP, outlines the design and key findings from a phase 2 trial of abiraterone plus olaparib vs each agent alone in mCRPC.

Telemedicine has also expanded access, allowing patients to choose either virtual or in-person visits. However, Kaylani Narra, MD, emphasized that limited genetic counseling capacity remains a major barrier.

According to Sophia Kamran, MD, innovation in bladder cancer is expanding treatment options and patient-centered care.

Vignesh T. Packiam, MD, reviews several bladder cancer studies from ASCO GU 2026 that he described as clinically meaningful for practicing urologists.

Rubenstein emphasizes the importance of strong clinical documentation and preparation by billing teams.

Laura Bukavina, MD, MPH, MSc, sat down to discuss the emerging role of ctDNA in guiding treatment decisions for patients with muscle-invasive bladder cancer, drawing on findings from the RETAIN and RETAIN 2 trials.

For asymptomatic renal stones, Mathew D. Sorensen, MD, MS, FACS, said he believes Break Wave could meaningfully influence the long-standing debate between surveillance and early intervention.

Robert S. Svatek, MD, discusses the background and key findings from the SWOG S1602 trial, evaluating BCG strain differences and intradermal BCG before intravesical therapy for patients with BCG-naïve NMIBC.

Sophia C. Kamran, MD, highlights some of the key bladder cancer trials presented at ASCO GU 2026 from the perspective of a radiation oncologist.

According to Alex Tatem, MD, misinformation online and aggressive marketing frequently push patients toward unregulated providers offering injectable silicone or other non-medical substances.

A permanent J code helps standardize billing and clarifies expected payment levels, often embedding reimbursement terms into payer contracts.

Matthew D. Galsky, MD, discusses what is needed for successful integration of BCG/ICI combinations in BCG-naive non–muscle invasive bladder cancer.

Kristen R. Scarpato, MD, MPH, discusses the potential role of emerging immunotherapy-based combinations in the treatment of BCG-naive, high-risk non–muscle invasive bladder cancer.

As immunotherapy and antibody-drug conjugates move earlier in treatment, questions about sequencing therapies are emerging.

Toni K. Choueiri, MD, discusses the background and key findings from the phase 3 LITESPARK-022 trial.

David R. Wise, MD, PhD, highlights initial findings from a phase 1b study of pasritamig plus docetaxel in patients with metastatic castration-resistant prostate cancer.

Fred Saad, MD, FRCP, highlights the background and key findings from the phase 1 PAnTHa study.

Pooja Ghatalia, MD, shares data from an integrated analysis of the RETAIN trials in muscle-invasive bladder cancer.

Stacy Loeb, MD, MSc, discusses a study evaluating levels of at microplastics and nanoplastics in prostate cancer tissue.

Enrique Gallardo, MD, discusses the final overall survival (OS) results from the EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in patients with metastatic castration-resistant prostate cancer.

Robert S. Svatek, MD, MSCI, highlights some of the greatest unmet needs in the non–muscle invasive bladder cancer space.

Leslie K. Ballas, MD, discusses the background and design for the phase 2 BRIGHT trial, evaluating a risk-adapted bladder preservation strategy in MIBC.

Melissa Moran, DO, explains how evolving approvals, careful off-label prescribing, and multidisciplinary collaboration can help clinicians address the high prevalence of hypoactive sexual desire disorder in peri- and postmenopausal women.

Austin Kirschner, MD, PhD, discusses the recent US commercial launch of the PROSTOX Standard test and its potential to inform radiation treatment decisions for patients with prostate cancer.

Tatem contrasts medically supervised treatments with rumored unsupervised or clandestine procedures.

Ezra J. Margolin, MD, highlights a recent study examining antibiotic prescribing patterns for patients presenting to the emergency department with kidney stones.